MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that studies show GRNOPC1, the company’s human embryonic stem cell (hESC)-based oligodendroglial progenitor therapeutic, produces multiple nerve growth factors, proteins that stimulate the survival and regeneration of neurons damaged during spinal cord injury.
